Neuromuscular Disease
Rycarma Therapeutics Inc. focuses on autosomal dominant RYR1-related myopathy, with interest in muscle function, weakness, and fatigability in adult patients. The clinical programme includes evaluation of skeletal muscle performance and related functional outcomes.
- Muscle strength
- Fatigability
- Functional mobility
The research activity includes assessment of treatment effects on day-to-day physical performance in a rare inherited myopathy.
Cardiac Rhythm Disorders
The sponsor also has interest in cardiac arrhythmias, reflecting involvement in disorders of heart rhythm and electrical stability. This area aligns with therapeutic work targeting abnormal cardiac conduction and rhythm control.
- Heart rhythm abnormalities
- Cardiac electrical activity
- Rhythm-related safety
This therapeutic domain supports clinical evaluation of agents intended to address rhythm disturbances in cardiovascular disease.
Muscle Function Assessment
Clinical research activity includes endpoints centered on muscle performance, with attention to strength, endurance, and physical exertion tolerance. Functional testing is used to capture changes in mobility and overall neuromuscular capacity.
- 1-minute sit-to-stand test
- Physical endurance
- Exercise tolerance
These measures are relevant to disorders where impaired muscle activation limits daily activity and independence.
Therapeutic Safety and Tolerability
The sponsor’s trials also examine safety, tolerability, and pharmacokinetics in relation to investigational therapy development. This area supports clinical work in both healthy volunteers and patients with inherited muscle disease.
- Safety monitoring
- Tolerability evaluation
- Pharmacokinetic profiling
These studies are part of the sponsor’s interest in advancing therapies for rare neuromuscular disorders and related cardiac conditions.
